Bromoenol lactone
Based on 3 publication(s) in Google Scholar
Bromoenol lactone ((6E)-Bromoenol lactone) is a suicide-based irreversible, selective, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β) with an IC50 value of approximately 7 μM, which inhibits antigen-stimulated mast cell exocytosis without blocking Ca2+ influx.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.59%
- CAS. Nr.: 88070-98-8
- Formel: C16H13BrO2
- Molecular Weight:317.18
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Lipid Metabolism Compound Library
HY-L091
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Bromoenol lactone
MoreAlle Phospholipase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
PLA2 7 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LNCaP | IC50 |
13 μM
Compound: rac-BEL
|
Antineoplastic activity against human LNCAP cells after 24 hrs by MTT assay
Antineoplastic activity against human LNCAP cells after 24 hrs by MTT assay
|
[PMID: 22677312] |
| LNCaP | IC50 |
5 μM
Compound: rac-BEL
|
Antineoplastic activity against human LNCAP cells after 48 hrs by MTT assay
Antineoplastic activity against human LNCAP cells after 48 hrs by MTT assay
|
[PMID: 22677312] |
| LNCaP | IC50 |
9 μM
Compound: rac-BEL
|
Antineoplastic activity against human LNCAP cells after 72 hrs by MTT assay
Antineoplastic activity against human LNCAP cells after 72 hrs by MTT assay
|
[PMID: 22677312] |
| PC-3 | IC50 |
14 μM
Compound: rac-BEL
|
Antineoplastic activity against human PC3 cells after 72 hrs by MTT assay
Antineoplastic activity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 22677312] |
| PC-3 | IC50 |
26 μM
Compound: rac-BEL
|
Antineoplastic activity against human PC3 cells after 48 hrs by MTT assay
Antineoplastic activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 22677312] |
| PC-3 | IC50 |
34 μM
Compound: rac-BEL
|
Antineoplastic activity against human PC3 cells after 24 hrs by MTT assay
Antineoplastic activity against human PC3 cells after 24 hrs by MTT assay
|
[PMID: 22677312] |
In RBL 2H3 and bone marrow-derived mast cells (BMMCs), Ca2+ entry is critical for exocytosis. Bromoenol lactone inhibits exocytosis when stimulated using a Ca2+ ionophore A23187, which passively transports Ca2+ down a concentration gradient and also in permeabilised mast cells where Ca2+ entry is no longer relevant. Moreover, Bromoenol lactone has only a minor effect on antigen- or thapsigargin-stimulated Ca2+ signalling, both the release from internal stores and sustained elevation due to Ca2+ influx[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 88070-98-8
-
Appearance Solid
-
Molecular Weight 317.18
-
Formel C16H13BrO2
-
Color White to yellow
-
SMILES
O=C1C(C2=C3C=CC=CC3=CC=C2)CC/C(O1)=C\Br
-
Synonyms
(6E)-Bromoenol lactone
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Front Pharmacol
Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice. [Abstract]2025 Mar 4:16:1491150. PMID: 40103591 -
Genomics
Orai2 deficiency attenutates experimental colitis by facilitating the colonization of Akkermansia muciniphila. [Abstract]2022 Sep 5;114(5):110479. PMID: 36070824 -
Cell Immunol
2024 Jun 17:401-402:104843. PMID: 38905771
Lösungsmittel & Löslichkeit
DMSO : 50 mg/mL (157.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (7.88 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (7.88 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Fensome-Green A, et al. Bromoenol lactone, an inhibitor of Group V1A calcium-independent phospholipase A2 inhibits antigen-stimulated mast cell exocytosis without blocking Ca2+ influx. Cell Calcium. 2007 Feb;41(2):145-53. [Content Brief]
[2]. Takuma T, et al. Role of Ca2+-independent phospholipase A2 in exocytosis of amylase from parotid acinar cells. J Biochem. 1997 Jun;121(6):1018-24. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1528 mL | 15.7639 mL | 31.5278 mL | 78.8196 mL |
| 5 mM | 0.6306 mL | 3.1528 mL | 6.3056 mL | 15.7639 mL | |
| 10 mM | 0.3153 mL | 1.5764 mL | 3.1528 mL | 7.8820 mL | |
| 15 mM | 0.2102 mL | 1.0509 mL | 2.1019 mL | 5.2546 mL | |
| 20 mM | 0.1576 mL | 0.7882 mL | 1.5764 mL | 3.9410 mL | |
| 25 mM | 0.1261 mL | 0.6306 mL | 1.2611 mL | 3.1528 mL | |
| 30 mM | 0.1051 mL | 0.5255 mL | 1.0509 mL | 2.6273 mL | |
| 40 mM | 0.0788 mL | 0.3941 mL | 0.7882 mL | 1.9705 mL | |
| 50 mM | 0.0631 mL | 0.3153 mL | 0.6306 mL | 1.5764 mL | |
| 60 mM | 0.0525 mL | 0.2627 mL | 0.5255 mL | 1.3137 mL | |
| 80 mM | 0.0394 mL | 0.1970 mL | 0.3941 mL | 0.9852 mL | |
| 100 mM | 0.0315 mL | 0.1576 mL | 0.3153 mL | 0.7882 mL |
Powered by Bioz